NFKB1 and gastric cancer: When combined, AKBA and cisplatin significantly increased p53 expression, reduced NF-κB levels, and promoted apoptosis in a dose-dependent manner, highlighting the potential for the use of AKBA as an adjuvant in the treatment of patients with gastric cancer [71].